Nautilus Bio (NAUT) Revenue & Revenue Breakdown
Nautilus Bio Revenue Highlights
Nautilus Bio Revenue by Period
Nautilus Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Nautilus Bio generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Nautilus Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $8.21M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | - |
Nautilus Bio generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Nautilus Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BEAM | Beam Therapeutics | $377.71M | $11.77M |
| KYMR | Kymera Therapeutics | $78.59M | $3.74M |
| DTIL | Precision BioSciences | $48.73M | $49.90M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| HCWB | HCW Biologics | $2.84M | $618.85K |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| FIXX | Q32 Bio | $1.16M | - |
| MNOV | MediciNova | $1.00M | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| CCCC | C4 Therapeutics | - | - |
| BCAB | BioAtla | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| NAUT | Nautilus Bio | - | - |
| CSBR | Champions Oncology | - | - |
NAUT Revenue FAQ
What is Nautilus Bio’s yearly revenue?
Nautilus Bio's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. NAUT's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Nautilus Bio’s quarterly revenue?
Nautilus Bio's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). NAUT's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023).
What is Nautilus Bio’s revenue growth rate?
Nautilus Bio's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.